I'm LongbridgeAI, I can summarize articles.UBS has downgraded CANSINOBIO's target price to HKD52.4 while maintaining a Buy rating. The company's 1Q26 results were in line with expectations, reporting a revenue of RMB190 million, a 38.7% year-on-year increase, but a net loss of RMB40 million. UBS has also revised its EPS forecasts for 2026 to 2028 downward, reflecting a more cautious outlook for the company.
UBS issued a research report stating that CANSINOBIO (06185.HK) -0.500 (-1.676%) Short selling $5.31M; Ratio 7.180% 's 1Q26 results were in line with expectations. During the period, revenue was RMB190 million, up 38.7% YoY, slightly above the bank's forecast of 34% growth for full-year 2026; net loss was RMB40 million, compared with the bank's forecast of a full-year profit of RMB337 million for 2026.
UBS revised the group's EPS forecasts for 2026 to 2028 downward from RMB1.36, RMB2.26 and RMB3.77 to RMB0.77, RMB2.15 and RMB3.58, respectively. The TP was cut from HKD59.8 to HKD52.4, with a Buy rating maintained. (hc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-29 16:25.)
This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.